rs1695
|
|
Non-Small Cell Lung Carcinoma
|
|
0.090 |
GeneticVariation
|
BEFREE |
CONCLUSIONS Polymorphisms of GSTP1 rs1695 and ABCC2 rs717620 can be used to predict the outcomes of Uygur patients with advanced NSCLC who have received platinum-based chemotherapy.
|
28442702 |
2017 |
rs1695
|
|
Non-Small Cell Lung Carcinoma
|
|
0.090 |
GeneticVariation
|
BEFREE |
In summary, we suggest that GSTP1 Ile105Val and XRCC1 Arg399Gln polymorphisms could influence the response to chemotherapy and sur-vival of advanced NSCLC.
|
27323109 |
2016 |
rs1695
|
|
Non-Small Cell Lung Carcinoma
|
|
0.090 |
GeneticVariation
|
BEFREE |
Moreover, individuals carrying both the G/A+G/G genotype of GSTP1 Ile105Val and the G/A+A/A of XRCC1 Arg194Trp were associated with heavy greater CR+PR response to chemotherapy (OR=2.98, 95% CI=1.39-6.42), and also correlated with longer overall survival of advanced NSCLC (HR=0.19, 95% CI=0.05-0.61).
|
26823821 |
2015 |
rs1695
|
|
Non-Small Cell Lung Carcinoma
|
|
0.090 |
GeneticVariation
|
BEFREE |
Presence of the GG genotype of GSTP1 rs1695 and the GA and AA genotypes of XRCC1 rs25487 was associated with overall survival of NSCLC, and the hazards ratios (95%CI) were 4.35 (1.40-17.92), 0.53 (0.31-0.91), and 0.39 (0.18-0.83), respectively.
|
26345972 |
2015 |
rs1695
|
|
Non-Small Cell Lung Carcinoma
|
|
0.090 |
GeneticVariation
|
BEFREE |
In the Cox proportional hazards model, GG genotype of GSTP1 A313G was significantly correlated with a longer median survival time when compared with AA genotype, and it is associated with a heavy decreased risk of death from NSCLC.
|
26097600 |
2015 |
rs1695
|
|
Non-Small Cell Lung Carcinoma
|
|
0.090 |
GeneticVariation
|
BEFREE |
Our study suggested that the GSTP1 A313G and GSTM1 null/present polymorphisms could predict the treatment response of the platinum-based chemotherapy in NSCLC patients, especially in East-Asian patients.
|
24729086 |
2014 |
rs1695
|
|
Non-Small Cell Lung Carcinoma
|
|
0.090 |
GeneticVariation
|
BEFREE |
Attention should be paid to MDR1 C3435T, G2677A/T and GSTP1 A313G for personalized chemotherapy treatment for NSCLC patients in Asian population in the future.
|
22761669 |
2012 |
rs1695
|
|
Non-Small Cell Lung Carcinoma
|
|
0.090 |
GeneticVariation
|
BEFREE |
The polymorphic status of MRP2 C-24T and GSTP1 Ile105Val might be the predictive markers for the treatment response of advanced NSCLC patients.
|
19568750 |
2010 |
rs1695
|
|
Non-Small Cell Lung Carcinoma
|
|
0.090 |
GeneticVariation
|
BEFREE |
In this study, CYP1A1 (Ile462Val), CYP1B1(Asn453Ser), GST M1, GSTP1 exon 5 (Ile105Val) and exon 6(Ala114Val) and GSTT1 polymorphisms were determined in 138 patients with advanced NSCLC to evaluate their role in survival.
|
20845989 |
2010 |
rs1138272
|
|
Non-Small Cell Lung Carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
In this study, CYP1A1 (Ile462Val), CYP1B1(Asn453Ser), GST M1, GSTP1 exon 5 (Ile105Val) and exon 6(Ala114Val) and GSTT1 polymorphisms were determined in 138 patients with advanced NSCLC to evaluate their role in survival.
|
20845989 |
2010 |
rs1394960893
|
|
Non-Small Cell Lung Carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
The genotypes at polymorphic sites of the glutathione S-transferase (GST) M1 (null/wildtype) and P1 (nucleotide 2627 A/G), myeloperoxidase (MPO) (nucleotide -463 G/A), X-ray repair cross-complementing group 1 (XRCC1) (nucleotides 26304 C/T; 28152 G/A), and NADPH quinine oxidoreductase (NQO1) (nucleotide 609 C/T) genes in 75 Chinese patients with non-small cell lung cancer (NSCLC) were characterized with polymerase chain reaction-restriction fragment length polymorphism.
|
16157195 |
2005 |
rs772503886
|
|
Non-Small Cell Lung Carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
Compared with single detection of genetic polymorphisms of GSTP1 Ile105Val or RRM1 C37A-T524C, joint detection of both may be more helpful for patients with NSCLC to receive gemcitabine-cisplatin regimens as the first-line chemotherapy.
|
26028097 |
2015 |